ProPhase Labs, Inc.

NasdaqCM:PRPH Voorraadrapport

Marktkapitalisatie: US$40.8m

ProPhase Labs Inkomsten in het verleden

Verleden criteriumcontroles 0/6

ProPhase Labs's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 27.4% per year.

Belangrijke informatie

-14.7%

Groei van de winst

-8.4%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroei27.4%
Rendement op eigen vermogen-59.7%
Nettomarge-146.4%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03
Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09
ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21
ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11
Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07
We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Jan 24
ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

Oct 13

ProPhase Labs Q2 2022 Earnings Preview

Aug 10

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Jul 26
We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 08
ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Mar 23
ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

Nov 30
Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Oct 20

Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Jul 22
Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

Jun 28

Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

May 14
Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing

May 06

A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Apr 12
A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Opbrengsten en kosten

Hoe ProPhase Labs geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:PRPH Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2418-26311
31 Mar 2429-24342
31 Dec 2344-17353
30 Sep 2363-10397
30 Jun 2379-4389
31 Mar 23947359
31 Dec 22123183413
30 Sep 22146312912
30 Jun 22131272811
31 Mar 22111182710
31 Dec 217962210
30 Sep 2139-5187
30 Jun 2133-2146
31 Mar 21280105
31 Dec 2015-271
30 Sep 2012-250
30 Jun 2011-250
31 Mar 209-350
31 Dec 1910-360
30 Sep 1911-360
30 Jun 1911-460
31 Mar 1912-360
31 Dec 1813-260
30 Sep 1813-160
30 Jun 1814-160
31 Mar 1813-160
31 Dec 1710-260
30 Sep 176-350
30 Jun 175-340
31 Mar 174-340
31 Dec 164-440
30 Sep 16-6-3-30
30 Jun 16-3-2-20
31 Mar 16-2-2-10
31 Dec 153-230
30 Sep 1521-3151
30 Jun 1522-7161
31 Mar 1522-8171
31 Dec 1422-8171
30 Sep 1423-7171
30 Jun 1424-2161
31 Mar 1424-1151
31 Dec 13250151

Kwaliteitswinsten: PRPH is currently unprofitable.

Groeiende winstmarge: PRPH is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: PRPH is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.

Versnelling van de groei: Unable to compare PRPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: PRPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement op eigen vermogen

Hoge ROE: PRPH has a negative Return on Equity (-59.69%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden